Abstract 3243: Drug-Eluting Stents for the Treatment of Left Main Coronary Arteries: A Comparison of Serial Angiographic Follow-Up with Sirolimus, Paclitaxel, Zotarolimus and Tacrolimus-Eluting Stent: Multicenter Registry in Asia
Background and Purpose: Drug-eluting stent have been proven to be effective in reducing restenosis in patients with left main coronary arteries (LMT). However, no studies comparing different drug-eluting stents in this complex subset are yet available. The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES) and Tacrolimus-eluting stent (TES) on the outcome of patients with LMT stenosis.
Methods: A prospective analysis of 501 patients with 501 LMT stenosis (248 SES, 172 PES, 52 ZES, 29 TES) in five high volume Asian centers after successful stenting in LMT stenosis was performed. The study endpoints were 30 days and 9 months major adverse cardiac events (MACE), 9 months angiographic restenosis and target lesion revascularization (TLR).
Results: The baseline clinical characteristics between 4 groups are similar. See table⇓ for clinical results.
Conclusion: The use of drug-eluting stents in patients with LMT stenosis was safe with low acute complication. Patients treated with SES showed lesser rate of restenosis compared with other drug-eluting stents.